Literature DB >> 4054195

Atenolol versus pindolol: side-effects in hypertension.

E C Foerster, P Greminger, W Siegenthaler, H Vetter, W Vetter.   

Abstract

This randomized crossover out-patient study was designed to compare the antihypertensive effects of atenolol and pindolol. After a wash-out period of two weeks in pretreated cases, 107 patients with essential hypertension were given either atenolol 100 mg once-daily or pindolol 20 mg slow release (SR) once-daily. Both atenolol and pindolol lowered blood pressure over the 24 week period. The diastolic blood pressure reduction was significantly greater (p less than 0.01) with atenolol than with pindolol. Before beta-blocker therapy, many patients had already experienced side-effects such as fatigue, sleep disturbances and dreams. This probably relates to the high sensitivity of the analogue scale used to assess side-effects, and to the high incidence of such symptoms in untreated patients. As the study progressed there was a reduction in the frequency of fatigue (p less than 0.03) and dreams (p less than 0.05) in both groups, whereas sleep disturbances significantly increased under pindolol (p less than 0.05) but decreased under atenolol (p less than 0.05). The only important side-effect difference between the two beta-blockers was the higher incidence of sleep disturbances with pindolol which may be due to the higher lipophilicity of this beta-blocker.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4054195     DOI: 10.1007/BF00543717

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

Review 1.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties.

Authors:  W Frishman
Journal:  Am Heart J       Date:  1979-05       Impact factor: 4.749

2.  Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension.

Authors:  R G Wilcox
Journal:  Br Med J       Date:  1978-08-05

3.  Pindolol: a comparison with other antihypertensive drugs and a double-blind placebo trial.

Authors:  H J Waal-Manning; F O Simpson
Journal:  N Z Med J       Date:  1974-08-28

Review 4.  The clinical importance of cardioselectivity and lipophilicity in beta blockers.

Authors:  J M Cruickshank
Journal:  Am Heart J       Date:  1980-08       Impact factor: 4.749

5.  A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.

Authors:  J J McNeil; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

6.  Atenolol and three nonselective beta-blockers in hypertension.

Authors:  H J Waal-Manning
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

7.  Atenolol in hypertension: follow-up of patients crossed over to this agent from propranolol, pindolol or metoprolol.

Authors:  D B Frewin; R K Penhall; P P Leonello; R J Clapp
Journal:  N Z Med J       Date:  1980-11-26
  7 in total
  3 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males.

Authors:  J B Kostis; R C Rosen; B C Holzer; C Randolph; L S Taska; M H Miller
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

Authors:  A Saheki; T Terasaki; I Tamai; A Tsuji
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.